Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

By afschroeder • November 15, 2025

Charles-Schoeman C, Zueger P, McDearmon-Blondell E, Fang S, Peng Y, Oishi T, Jain M, Tesser J. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatol Ther. 2025 Nov 14. doi: 10.1007/s40744-025-00808-z. Epub ahead of print. PMID: 41239038.

Tags: Biologic disease-modifying antirheumatic drug(bDMARD), Clinical Disease Activity Index(CDAI), Publications, Rheumatoid arthritis(RA), Rheumatology, Tumor necrosis factor inhibitor(TNFi)

DASC-LOT Framework and S3 Metric: A Novel Evaluation and Benchmarking Method to Assess Initiation, Duration, and Spectrum of Antimicrobial Usage at Inpatient Hospital Settings

Goto M, Imai S, Cho H, Merchant JA, Goetz MB, Perencevich EN, Alexander B, Shi Q, Holcombe A, Livorsi DJ. DASC-LOT Framework and S3 Metric:[...]

A Hierarchical and Multiscale Framework for Characterizing Mouse Sleep-Wake Dynamics from 14-Day Continuous EEG: Validation of Age- and Sex-Dependent Remodeling

Kostin A, Saevskiy A, Alam MA, Jiang Y, Suntsova N, Alam MN. A Hierarchical and Multiscale Framework for Characterizing Mouse Sleep-Wake Dynamics from 14-Day Continuous[...]

Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions

Hermann JN, Kruger SE, Wodniak N, Holland J, Janosick V, Sanchez A, Zuniga-Moya JC, Brucker D, Torres B, Melo KM, Oliveros E, Kuran R, D'Assumpcao[...]